McDonald, V. Et Al. 2023. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet , vol.402, no.10413 , 1648-1659.

McDonald, V., Miyakawa, Y., Carpenedo, M., Kuter, D. J., Al-Samkari, H., Bussel, J. B., ... Godar, M.(2023). Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet , vol.402, no.10413, 1648-1659.

McDonald, Vickie Et Al. "Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial," The Lancet , vol.402, no.10413, 1648-1659, 2023

McDonald, Vickie Et Al. "Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial." The Lancet , vol.402, no.10413, pp.1648-1659, 2023

McDonald, V. Et Al. (2023) . "Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial." The Lancet , vol.402, no.10413, pp.1648-1659.

@article{article, author={Vickie McDonald Et Al. }, title={Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial}, journal={The Lancet}, year=2023, pages={1648-1659} }